This is a Myasthenia news story, published by Yahoo, that relates primarily to Inebilizumab news.
For more Myasthenia news, you can click here:
more Myasthenia newsFor more Inebilizumab news, you can click here:
more Inebilizumab newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
inebilizumab. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest FDA news, active ingredient efgartigimod news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
experimental drugReuters
•77% Informative
Inebilizumab helped improve daily activities including chewing and swallowing in patients suffering from a rare muscle-weakening disease.
Myasthenia gravis is caused by an abnormal immune reaction that weakens the muscles that control the eyes, mouth, throat and limbs.
Shares of Amgen fell about 2% to $ 325 in extended trading.
VR Score
87
Informative language
95
Neutral language
9
Article tone
formal
Language
English
Language complexity
69
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links